116 related articles for article (PubMed ID: 9095206)
1. Evaluation of chemotherapy and radiation enhancement and 31P NMR spectral changes induced by biochemical modulation.
Koutcher JA; Alfieri AA; Tsai JC; Matei C; Stolfi RL; Ballon D; Martin DS
Cancer Invest; 1997; 15(2):111-20. PubMed ID: 9095206
[TBL] [Abstract][Full Text] [Related]
2. In vivo detection by 31P NMR of pentose phosphate pathway block secondary to biochemical modulation.
Mahmood U; Street JC; Matei C; Ballon D; Martin DS; Koutcher JA
NMR Biomed; 1996 May; 9(3):114-20. PubMed ID: 8892397
[TBL] [Abstract][Full Text] [Related]
3. Radiation enhancement by biochemical modulation and 5-fluorouracil.
Koutcher JA; Alfieri AA; Thaler H; Matei C; Martin DS
Int J Radiat Oncol Biol Phys; 1997 Dec; 39(5):1145-52. PubMed ID: 9392557
[TBL] [Abstract][Full Text] [Related]
4. Apoptosis induced in advanced CD8F1-murine mammary tumors by the combination of PALA, MMPR and 6AN precedes tumor regression and is preceded by ATP depletion.
Nord LD; Stolfi RL; Alfieri AA; Netto G; Reuter V; Sternberg SS; Colofiore JR; Koutcher JA; Martin DS
Cancer Chemother Pharmacol; 1997; 40(5):376-84. PubMed ID: 9272113
[TBL] [Abstract][Full Text] [Related]
5. Correlation of retention of tumor methylmercaptopurine riboside-5'-phosphate with effectiveness in CD8F1 murine mammary tumor regression.
Nord LD; Stolfi RL; Colofiore JR; Martin DS
Biochem Pharmacol; 1996 Mar; 51(5):621-7. PubMed ID: 8615898
[TBL] [Abstract][Full Text] [Related]
6. Biochemical modulation of tumor cell energy in vivo: II. A lower dose of adriamycin is required and a greater antitumor activity is induced when cellular energy is depressed.
Martin DS; Stolfi RL; Colofiore JR; Nord LD; Sternberg S
Cancer Invest; 1994; 12(3):296-307. PubMed ID: 8187007
[TBL] [Abstract][Full Text] [Related]
7. Biochemical modulation of tumor cell energy. IV. Evidence for the contribution of adenosine triphosphate (ATP) depletion to chemotherapeutically-induced tumor regression.
Colofiore JR; Stolfi RL; Nord LD; Martin DS
Biochem Pharmacol; 1995 Nov; 50(11):1943-8. PubMed ID: 8615876
[TBL] [Abstract][Full Text] [Related]
8. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine riboside: optimization of 6-methylmercaptopurine riboside dose and schedule through biochemical analysis of sequential tumor biopsy specimens.
O'Dwyer PJ; Hudes GR; Colofiore J; Walczak J; Hoffman J; LaCreta FP; Comis RL; Martin DS; Ozols RF
J Natl Cancer Inst; 1991 Sep; 83(17):1235-40. PubMed ID: 1714507
[TBL] [Abstract][Full Text] [Related]
9. Marked enhancement in vivo of paclitaxel's (taxol's) tumor-regressing activity by ATP-depleting modulation.
Martin DS; Stolfi RL; Colofiore JR; Nord LD
Anticancer Drugs; 1996 Aug; 7(6):655-9. PubMed ID: 8913434
[TBL] [Abstract][Full Text] [Related]
10. Effect of 6-aminonicotinamide on the pentose phosphate pathway: 31P NMR and tumor growth delay studies.
Koutcher JA; Alfieri AA; Matei C; Meyer KL; Street JC; Martin DS
Magn Reson Med; 1996 Dec; 36(6):887-92. PubMed ID: 8946354
[TBL] [Abstract][Full Text] [Related]
11. Potentiation of a three drug chemotherapy regimen by radiation.
Koutcher JA; Alfieri AA; Stolfi RL; Devitt ML; Colofiore JR; Nord LD; Martin DS
Cancer Res; 1993 Aug; 53(15):3518-23. PubMed ID: 8339257
[TBL] [Abstract][Full Text] [Related]
12. Biochemical modulation of tumor cell energy: regression of advanced spontaneous murine breast tumors with a 5-fluorouracil-containing drug combination.
Stolfi RL; Colofiore JR; Nord LD; Koutcher JA; Martin DS
Cancer Res; 1992 Aug; 52(15):4074-81. PubMed ID: 1379119
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of PALA and 6-methylmercaptopurine riboside (MMPR) in combination with 5-fluorouracil in advanced pancreatic cancer.
Redei I; Green F; Hoffman JP; Weiner LM; Scher R; O'Dwyer PJ
Invest New Drugs; 1994; 12(4):319-21. PubMed ID: 7775133
[TBL] [Abstract][Full Text] [Related]
14. Enhanced antitumor activity of an adriamycin + 5-fluorouracil combination when preceded by biochemical modulation.
Stolfi RL; Colofiore JR; Nord LD; Martin DS
Anticancer Drugs; 1996 Jan; 7(1):100-4. PubMed ID: 8742105
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside.
Hageboutros A; Hudes GR; Brennan J; Green F; Hoffman J; LaCreta FP; Colofiore J; Martin DS; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1996; 37(3):229-34. PubMed ID: 8529282
[TBL] [Abstract][Full Text] [Related]
16. Quantitation of metabolic and radiobiological effects of 6-aminonicotinamide in RIF-1 tumor cells in vitro.
Street JC; Alfieri AA; Koutcher JA
Cancer Res; 1997 Sep; 57(18):3956-62. PubMed ID: 9307279
[TBL] [Abstract][Full Text] [Related]
17. Cancer chemotherapy: past is prologue.
Martin DS
Mt Sinai J Med; 1985 Jun; 52(6):426-34. PubMed ID: 3875021
[No Abstract] [Full Text] [Related]
18. N-(phosphonacetyl)-L-aspartate synergistically enhances the cytotoxicity of 5-fluorouracil/interferon-alpha-2a against human colon cancer cell lines.
Wadler S; Mao X; Bajaj R; Hallam S; Schwartz EL
Mol Pharmacol; 1993 Nov; 44(5):1070-6. PubMed ID: 8246910
[TBL] [Abstract][Full Text] [Related]
19. Five-chlorodeoxycytidine and biomodulators of its metabolism result in fifty to eighty percent cures of advanced EMT-6 tumors when used with fractionated radiation.
Greer S; Schwade J; Marion HS
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(4):1059-69. PubMed ID: 7607927
[TBL] [Abstract][Full Text] [Related]
20. Murine pharmacokinetics of 6-aminonicotinamide (NSC 21206), a novel biochemical modulating agent.
Walker DL; Reid JM; Svingen PA; Rios R; Covey JM; Alley MC; Hollingshead MG; Budihardjo II; Eckdahl S; Boerner SA; Kaufmann SH; Ames MM
Biochem Pharmacol; 1999 Sep; 58(6):1057-66. PubMed ID: 10509758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
